Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc. - Common Stock (NQ:ONCY)

0.8720 +0.0320 (+3.81%)
Streaming Delayed Price Updated: 10:16 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncolytics Biotech Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Oncolytics Biotech® Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Trial is designed to advance pelareorep’s clinical development in China, the world’s second-largest pharmaceutical market San Diego, CA and Calgary, AB – October 14, 2021 — Oncolytics Biotech® Inc.... 
Via FinancialNewsMedia
New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space
Via FinancialNewsMedia
News headline image
Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer ↗
Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: ... 
Via Benzinga
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Via FinancialNewsMedia
Topics Death
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
Via FinancialNewsMedia
News headline image
Oncolytics Biotech's Pelareorep Associated With Therapeutic Efficacy, Improved Clinical Outcomes In Breast Cancer ↗
Oncolytics Biotech Inc (NASDAQ: ONCY), together with SOLTI, has announced new clinical data from the AWARE-1 window-of-opportunity breast cancer study... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2021 ↗
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes ↗
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
News headline image
55 Biggest Movers From Yesterday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
News headline image
51 Biggest Movers From Friday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.